secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001493152-25-001603
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement
--------------------------------------------------------------------------------

- Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.
- 90% of high galectin-3 NSCLC patients failed to respond to ICI after 3 treatments.
- Surface Plasmon Resonance and cryo-EM confirm galectin-3 blocks ICI binding to PD-1 receptor.
- Company also published cancer presentation on galectin antagonists in cancer.
- CEO states findings herald significant shift in cancer treatment paradigms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315225001603/0001493152-25-001603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315225001603/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer